RNA-binding protein PUM2 regulates mesenchymal stem cell fate via repression of JAK2 and RUNX2 mRNAs.
Myon-Hee LeeXinjun WuYong ZhuPublished in: Journal of cellular physiology (2019)
The differentiation of mesenchymal stem cells (MSCs) into unwanted lineages can generate potential problems in clinical trials. Thus, understanding the molecular mechanisms, involved in this process, would help prevent unexpected complications. Regulation of gene expression, at the posttranscriptional level, is a new approach in cell therapies. PUMILIO is a conserved posttranscriptional regulator. However, the underlying mechanisms of PUMILIO, in vertebrate stem cells, remain elusive. Here, we show that depletion of PUMILIO2 (PUM2) blocks MSC adipogenesis and enhances osteogenesis. We also demonstrate that PUM2 works as a negative regulator on the 3'-untranslated regions of JAK2 and RUNX2 via direct binding. CRISPR/Cas9-mediated gene silencing of Pum2 inhibited lipid accumulation and induced excessive bone formation in zebrafish larvae. Our findings reveal novel roles of PUM2 in MSCs and provide potential therapeutic targets for related diseases.
Keyphrases
- mesenchymal stem cells
- transcription factor
- stem cells
- gene expression
- binding protein
- umbilical cord
- crispr cas
- cell therapy
- cell fate
- clinical trial
- bone marrow
- single cell
- dna binding
- genome editing
- dna methylation
- mental health
- human health
- high glucose
- type diabetes
- genome wide
- drug induced
- adipose tissue
- metabolic syndrome
- weight gain
- risk assessment
- body mass index
- zika virus
- high fat diet induced
- aedes aegypti